New drug aims to calm heart arteries after attack

NCT ID NCT07276282

Not yet recruiting Disease control Sponsor: ECRI bv Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new drug called ziltivekimab can help stabilize the fatty plaques in heart arteries after a heart attack. About 332 participants who recently had a heart attack will be randomly assigned to receive either the new drug or a placebo injection once a month, in addition to their standard care. Doctors will use special imaging to look inside the heart arteries over 15 months to see if the drug reduces dangerous plaque buildup and makes plaques less likely to rupture.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bern University Hospital, Inselspital Bern

    Bern, Switzerland

    Contact

Conditions

Explore the condition pages connected to this study.